{"id":828206,"date":"2025-03-20T16:03:39","date_gmt":"2025-03-20T20:03:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/"},"modified":"2025-03-20T16:03:39","modified_gmt":"2025-03-20T20:03:39","slug":"acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/","title":{"rendered":"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025"},"content":{"rendered":"
\n

NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc.<\/a> (NASDAQ: ABOS) (\u201cAcumen\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer\u2019s disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.\u00a0\u00a0<\/p>\n

To participate in the live conference call, please register using this\u202flink<\/a>. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.\u202f\u202f\u00a0<\/p>\n

The webcast audio will be available via this\u202flink<\/a>.<\/p>\n

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company’s website at\u00a0www.acumenpharm.com<\/a>.<\/p>\n

\n About Acumen Pharmaceuticals, Inc.<\/strong>\n <\/p>\n

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD). Acumen\u2019s scientific founders pioneered research on A\u03b2Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer\u2019s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble A\u03b2Os, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer\u2019s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit\u00a0www.acumenpharm.com<\/a>.\u00a0<\/p>\n

\n Investors: <\/strong>
\n
Alex Braun
abraun@acumenpharm.com<\/a><\/p>\n

\n Media:<\/strong>\u00a0
AcumenPR@westwicke.com<\/u><\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (\u201cAcumen\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer\u2019s disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.\u00a0\u00a0 To participate in the live conference call, please register using this\u202flink. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.\u202f\u202f\u00a0 The webcast audio will be available via this\u202flink. An archived … <\/p>\n

Continue reading “Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-828206","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (\u201cAcumen\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer\u2019s disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.\u00a0\u00a0 To participate in the live conference call, please register using this\u202flink. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.\u202f\u202f\u00a0 The webcast audio will be available via this\u202flink. An archived … Continue reading "Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T20:03:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Nzk2OCM2ODE2MDYyIzIyMTA2ODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025\",\"datePublished\":\"2025-03-20T20:03:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/\"},\"wordCount\":281,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Nzk2OCM2ODE2MDYyIzIyMTA2ODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/\",\"name\":\"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Nzk2OCM2ODE2MDYyIzIyMTA2ODI=\",\"datePublished\":\"2025-03-20T20:03:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Nzk2OCM2ODE2MDYyIzIyMTA2ODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Nzk2OCM2ODE2MDYyIzIyMTA2ODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/","og_locale":"en_US","og_type":"article","og_title":"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - Market Newsdesk","og_description":"NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (\u201cAcumen\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer\u2019s disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.\u00a0\u00a0 To participate in the live conference call, please register using this\u202flink. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.\u202f\u202f\u00a0 The webcast audio will be available via this\u202flink. An archived … Continue reading \"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-20T20:03:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Nzk2OCM2ODE2MDYyIzIyMTA2ODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025","datePublished":"2025-03-20T20:03:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/"},"wordCount":281,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Nzk2OCM2ODE2MDYyIzIyMTA2ODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/","name":"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Nzk2OCM2ODE2MDYyIzIyMTA2ODI=","datePublished":"2025-03-20T20:03:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Nzk2OCM2ODE2MDYyIzIyMTA2ODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Nzk2OCM2ODE2MDYyIzIyMTA2ODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-27-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=828206"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828206\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=828206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=828206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=828206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}